Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06876571

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

Sponsor: Invivoscribe, Inc.

View on ClinicalTrials.gov

Summary

This protocol describes the pivotal accuracy study for the IdentiClone Dx TRG Assay. The intent of the accuracy study is to demonstrate agreement between the results of the IC TRG Dx Assay and a predicate devise or assay on retrospective and residual de-identified DNA extracted from FFPE (Formalin Fixed Paraffin Embedded) samples from individuals with suspected T-Cell Lymphoproliferations. The predicate device will be the LymphoTrack Dx TRG (FR1/FR2/FR3) Assays - MiSeq (LT Dx TRG-CE-IVD), which is a CE-IVD assay with a similar intended use as the IC TRG Assay on the same sample type.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

250

Start Date

2025-06-02

Completion Date

2025-12-06

Last Updated

2025-03-14

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

IdentiClone Dx TRG Assay

The IdentiClone Dx TRG Assay ("Assay") is an in vitro diagnostic product intended for qualitative capillary electrophoresis based-detection of clonality in T-cell receptor gamma chain (TRG) gene rearrangements in Formalin-Fixed Paraffin-Embedded (FFPE) specimens as an adjunctive method for the diagnosis of T-cell lymphoproliferative disease. This qualitative, non-automated Assay is for use on the ABI 3500xL Dx and ABI 3500xL Genetic Analyzers.

Locations (3)

Invivoscribe, Inc.

San Diego, California, United States

LabPMM GmbH

Hallbergmoos, Germany

LabPMM GK

Kawasaki-shi, Kanagawa, Japan